Background: We performed a meta-analysis to compare overall survival (OS) outcomes in patients with synchronous oligometastatic non-small cell lung cancer (NSCLC) who underwent aggressive thoracic therapy (ATT) with those who did not.
Methods: A systematic review of controlled trials of ATT on survival in synchronous oligometastatic NSCLC was conducted. Hazard ratio (HR) for the main endpoint OS was pooled using a fixed-effects model. Subgroup analysis was performed in patients with single organ metastases, or with different numbers of brain metastases, or with different stages of thoracic disease. Pooled survival curves of OS were constructed.
Results: Seven eligible retrospective observational cohort studies were identified including 668 synchronous oligometastatic NSCLC patients, of whom 227 (34.0%) received ATT. For patients with synchronous oligometastatic NSCLC, ATT was associated with a significant improvement of OS (HR, 0.48; 95% CI, 0.39-0.60; P<0.00001). In subgroup analysis, the association with OS was similar or even strengthened, with a HR of 0.42 (95% CI, 0.31-0.56) in single organ metastases group, 0.49 (95% CI, 0.31-0.75) in solitary brain metastasis group, and 0.38 (95% CI, 0.20-0.73) in thoracic stage I-II group, respectively. The pooled cumulative survival rates for patients received ATT were 74.9% at 1 year, 52.1% at 2 years, 23.0% at 3 years, and 12.6% at 4 years. The corresponding pooled survival for patients who did not receive ATT were 32.3%, 13.7%, 3.7%, and 2.0%, respectively.
Conclusions: Survival benefit from ATT is common in synchronous oligometastatic patients. Selected patients with synchronous oligometastatic NSCLC could also achieve long-term survival with ATT.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5334109 | PMC |
| http://dx.doi.org/10.21037/jtd.2017.02.21 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Oligometastatic Disease Is Not an Absolute Contraindication to Pelvic Exenteration in Selected Patients With Locally Recurrent Rectal Cancer.
Dis Colon Rectum
December 2024
Surgical Outcomes Research Centre (SOuRCe), Royal Prince Alfred Hospital, Sydney, Australia.
Background: The treatment of locally recurrent rectal cancer has evolved dramatically in recent decades. As the boundaries of exenterative surgery continue to be pushed, one of the unanswered and controversial questions is the role of radical salvage surgery for locally recurrent rectal cancer in the setting of oligometastatic disease.
Objective: To investigate the impact of synchronous or previously treated distant metastases on survival following pelvic exenteration for locally recurrent rectal cancer.
Metastasis-directed stereotactic radiotherapy in patients with breast cancer: results of an international multicenter cohort study.
Clin Exp Metastasis
December 2024
Department of Radiation Oncology, University Hospital Schleswig-Holstein Campus Kiel, Arnold-Heller-Str.3, 24105, Kiel, Germany.
Metastasis-directed therapy (MDT) for oligometastatic breast cancer (≤ 5 metastases) has shown little effect in specific scenarios of randomized trials. Therefore, we aimed to assess outcomes after metastasis-directed stereotactic radiotherapy (SRT) in various clinical scenarios. We conducted an international retrospective cohort study in thirteen centers including breast cancer patients receiving SRT to any metastatic site.
View Article and Find Full Text PDFLong-term outcomes of surgical treatment of non-small cell lung cancer with oligometastatic disease involving only the brain in the era of PET/CT.
J Cardiothorac Surg
December 2024
Department of General Thoracic Surgery, Osaka International Cancer Institute, 1,3,4: 3-1-69, Otemae, Chuo-Ku, Osaka, 541-8567, Japan.
Background: The prognosis of patients with synchronous oligometastatic non-small cell lung cancer (NSCLC) has been improving owing to advancements in imaging techniques and new treatment approaches such as tyrosine kinase inhibitors. This study aimed to investigate the long-term outcomes, including the clinical course after recurrence, of patients with synchronous oligometastatic NSCLC with only brain metastases, treated with bifocal treatment.
Methods: We retrospectively analyzed 22 patients with clinical T1-4 and N0-1 NSCLC with synchronous brain metastases who were diagnosed by preoperative PET/CT and brain CT or MRI and underwent pulmonary resection for the primary site and surgery or radiation therapy for brain metastases at our institution from 2005 to 2019.
Introduction And Aim Of The Study: The impact of surgical therapy in selected patients with limited metastatic/recurrence burden have not yet been well studied. We investigated the outcome of surgical resection for patients with local recurrence only or oligometastatic UC of the bladder.
Patients And Methods: We identified patients with oligometastatic UC or local recurrence only after radical cystectomy (RC) who underwent surgical resection with curative intent between 2003 and 2022 at our center.
Challenges in the Understanding of Oligometastatic Disease in Clinical Practice.
Cureus
October 2024
Department of Radiation Oncology, Princess Margaret Cancer Centre, Toronto, CAN.
Unlabelled: Introduction There is little data describing oligometastatic disease (OMD) and decision-making. We sought to understand the knowledge gaps and challenges in deciphering and delivering treatments.
Materials And Methods: This is a quality improvement (QI) study conducted via an anonymous survey.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!